Intravenous Pamidronate for Refractory Lymphedema

Intravenous Pamidronate for Refractory Lymphedema

Beigi AA¹ ; Sadeghi AM² ; Masoudpour H³ ; Shirazinejad S⁴ ; Mottaghi P⁵

Show Affiliations

1. Department of Vascular Surgery, Isfahan University of Medical Sciences, Alzahra Hospital, Isfahan, Iran
2. Department of Surgery, Kashan University of Medical Sciences, Kashan, Iran
3. Department of Surgery, Isfahan University of Medical Sciences, Alzahra Hospital, Isfahan, Iran
4. Department of Radiology, Isfahan University of Medical Sciences, Alzahra Hospital, Isfahan, Iran
5. Department of Internal Medicine, Isfahan University of Medical Sciences, Alzahra Hospital, Isfahan, Iran

Source: Iranian Red Crescent Medical Journal Published:2011

Abstract

Background: Based on beneficial reports of pamidronate use for reflex sympathetic dystrophy in reduction of pain and swelling, this drug can be studied as a novel treatment for refractory lymphedema. This study aims to determine the effectiveness of pamidronate on lymphedema and its possible side effects. Methods: Twelve cases of lower limb refractory lymphedema were enrolled. They received intravenous pamidronate monthly for 3 consecutive months and were followed by measuring any discomfort with visual analog scale (VAS) and physician global assessment, based on objective signs of limb volume and circumference. Results: The limb volume, circumference, and satisfaction of the patients improved significantly. Conclusion: Pamidronate when is added to conservative treatments may reduce lymphedema and improve the patient's comfort. © Iranian Red Crescent Medical Journal.

Related Docs

1. Pamidronate Infusion Improved Two Cases of Intractable Seronegative Rheumatoid Arthritise, Journal of Research in Medical Sciences (2011)

2. A Multicentre Cross-Sectional Study of Arm Lymphedema Four or More Years After Breast Cancer Treatment in Iranian Patients, Breast Cancer (2010)

3. Factors Associated With the Severity of Lymphedema After the Treatment of Invasive Breast Cancers, Journal of Isfahan Medical School (2013)

4. Intravenous Pamidronate for Refractory Rheumatoid Arthritis, Journal of Research in Medical Sciences (2012)

Experts (# of related papers)

View all Related Experts

Mansour Salesi (2)

Peyman Mottaghi (2)

Style	Citing Format
MLA	Beigi AA, et al.. "Intravenous Pamidronate for Refractory Lymphedema." Iranian Red Crescent Medical Journal, vol. 13, no. 4, 2011, pp. 263-266.
APA	Beigi AA, Sadeghi AM, Masoudpour H, Shirazinejad S, Mottaghi P (2011). Intravenous Pamidronate for Refractory Lymphedema. Iranian Red Crescent Medical Journal, 13(4), 263-266.
Chicago	Beigi AA, Sadeghi AM, Masoudpour H, Shirazinejad S, Mottaghi P. "Intravenous Pamidronate for Refractory Lymphedema." Iranian Red Crescent Medical Journal 13, no. 4 (2011): 263-266.
Harvard	Beigi AA et al. (2011) 'Intravenous Pamidronate for Refractory Lymphedema', Iranian Red Crescent Medical Journal, 13(4), pp. 263-266.
Vancouver	Beigi AA, Sadeghi AM, Masoudpour H, Shirazinejad S, Mottaghi P. Intravenous Pamidronate for Refractory Lymphedema. Iranian Red Crescent Medical Journal. 2011;13(4):263-266.
BibTex	@article{ author = {Beigi AA and Sadeghi AM and Masoudpour H and Shirazinejad S and Mottaghi P}, title = {Intravenous Pamidronate for Refractory Lymphedema}, journal = {Iranian Red Crescent Medical Journal}, volume = {13}, number = {4}, pages = {263-266}, year = {2011} }
RIS	TY - JOUR AU - Beigi AA AU - Sadeghi AM AU - Masoudpour H AU - Shirazinejad S AU - Mottaghi P TI - Intravenous Pamidronate for Refractory Lymphedema JO - Iranian Red Crescent Medical Journal VL - 13 IS - 4 SP - 263 EP - 266 PY - 2011 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract